GLYCONEX
GlycoNex develops and licenses anti-cancer monoclonal antibodies.
GLYCONEX
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2001-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.glyconex.com.tw
Total Employee:
101+
Status:
Active
Contact:
886-2-2697-4168
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Font Awesome Nginx Microsoft Exchange Online Office 365 Mail PHP PHP 7
Similar Organizations
Hybritech Incorporated
Hybritech Incorporated develops and markets monoclonal antibodies.
Vcell Healthcare
Vcell Healthcare is a developer and manufacturer of monoclonal antibody biosimilar products.
VDJ
VDJ is an antibody drug research and development enterprise.
More informations about "GlycoNex"
GlycoNex INC.
Except for mAb new drugs, GlycoNex has also biosimilar products. To date, the development of mAb cancer drugs has made tremendous progress. The first mAb candidate has been …See details»
GlycoNex - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number 886-2-2697-4168; Products and Services. Powered by AI . Edit Products and Services Section. …See details»
財團法人醫藥工業技術發展中心 - pitdc.org.tw
[email protected]. TEL +886-2-2697-4168. Company Introduction. GlycoNex Inc. was founded in 2001. We have grown to be the pioneer in Taiwan that combines glycotechnologies …See details»
GlycoNex - Products, Competitors, Financials, Employees, …
Glyconex.com.tw. Overview & Products; Financials; Founded Year 2001. Stage Grant | Alive. ... In December2024, GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage …See details»
GlycoNex Incorporation Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GlycoNex Incorporation of New Taipei City, New Taipei. Get the latest business insights from Dun & …See details»
GlycoNex Company Profile - Office Locations, Competitors, …
Oct 29, 2024 GlycoNex (台灣醣聯生技醫藥股) is a company developing cancer drugs utilizing glycosphingolipid antigen and human monoclonal antibody technologies. Its platform enables …See details»
GlycoNex INC.
2024-12-17 GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar Read More. 2024-11-12 GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial …See details»
醣聯 GlycoNex Inc.-公司投資人關係整合平台 TDCC IR Platform
4168 醣聯 GlycoNex Inc. Company Information. Website： http://www.glyconex.com.tw/ Address：8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 22175 ...See details»
GlycoNex - Overview, News & Similar companies | ZoomInfo.com
GlycoNex contact info: Phone number: +886 226971168 Website: www.glyconex.com.tw What does GlycoNex do? The transient expression system and antibody evaluation platform of …See details»
GlycoNex Inc. - Company Profile & Staff Directory - ContactOut
GlycoNex Inc. was founded in 2001, in alliance with The Biomembrane Institute (TBI) from Washington University and Dr. Sen-Itiroh Hakomori, a member of the National Academy of …See details»
GlycoNex Incorporation Company Description - Stock Analysis
Nov 27, 2024 GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. ...See details»
GlycoNex Company Profile 2025: Stock Performance & Earnings
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has …See details»
GlycoNex INC.
獨立董事與稽核主管及會計師溝通情形. 獨立董事與內部稽核主管及簽證會計師有直接聯繫之管道，並得視需要以電子郵件、電話或會面方式溝通；且依主管機關之規定，對公司財務、業務狀 …See details»
Glyconex Incorporation Company Profile - Taiwan, China - EMIS
Jul 5, 2024 It GlycoNex has grown to be the pioneer in Taiwan that combines glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs. Marching into …See details»
Nextsource | Company Profile | GlycoNex
Explore the company profile of GlycoNex (glyconex.com.tw) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual …
5 days ago NEW TAIPEI CITY, Taiwan, April 28, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the …See details»
GlycoNex INC.
GlycoNex has been developing antibody drugs for 20 years. Our experiences and solutions in this field cover antibody generation and engineering, cell line development, analytical …See details»
GLYCONEX INC. - 公司登記查詢中心
英文簡稱：GlycoNex Inc. 股票代碼： 4168 目前股價： 2024-03-30 02:47:38 25 0.35See details»
GlycoNex INC.
In this regard, GlycoNex has been developing GNX201, an anti-TACA pro-antibody that applies a proprietary “Antibody Lock” technology by fusing a masking peptide to the variable region of …See details»
GlycoNex INC.
Address 8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, TaiwanSee details»